463 related articles for article (PubMed ID: 26682462)
1. Antitumor Efficacy of Bacillus Calmette-Guerin Loaded Cationic Nanoparticles for Intravesical Immunotherapy of Bladder Tumor Induced Rat Model.
Erdoğar N; Iskit AB; Eroğlu H; Sargon MF; Mungan NA; Bilensoy E
J Nanosci Nanotechnol; 2015 Dec; 15(12):10156-64. PubMed ID: 26682462
[TBL] [Abstract][Full Text] [Related]
2. Cationic core-shell nanoparticles for intravesical chemotherapy in tumor-induced rat model: safety and efficacy.
Erdogar N; İskit AB; Eroglu H; Sargon MF; Mungan NA; Bilensoy E
Int J Pharm; 2014 Aug; 471(1-2):1-9. PubMed ID: 24836669
[TBL] [Abstract][Full Text] [Related]
3. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.
Lamm DL; van der Meijden PM; Morales A; Brosman SA; Catalona WJ; Herr HW; Soloway MS; Steg A; Debruyne FM
J Urol; 1992 Mar; 147(3):596-600. PubMed ID: 1538436
[TBL] [Abstract][Full Text] [Related]
4. Drug-Loaded Bacillus Calmette-Guérin Bacteria for Immuno-Chemo Combo Therapy in Bladder Cancer.
Liu K; Wang L; Peng J; Lyu Y; Li Y; Duan D; Zhang W; Wei G; Li T; Niu Y; Zhao Y
Adv Mater; 2024 May; 36(19):e2310735. PubMed ID: 38330363
[TBL] [Abstract][Full Text] [Related]
5. [Miliary Pulmonary Tuberculosis After Intravesical BCG Instillation in a Patient with High-Grade Bladder Cancer].
Gözüküçük R; Çakıroğlu B
Mikrobiyol Bul; 2023 Oct; 57(4):675-681. PubMed ID: 37885395
[TBL] [Abstract][Full Text] [Related]
6. Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis.
Huang Z; Liu H; Wang Y; Zhang C; Xu T
Curr Med Res Opin; 2017 Aug; 33(8):1379-1387. PubMed ID: 28471272
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Intravesical Bacillus Calmette-Guérin Immunotherapy in Patients with Non-Muscle-Invasive Bladder Cancer Presenting with Asymptomatic Bacteriuria: A Systematic Review.
Poletajew S; Zapała P; Radziszewski P
Urol Int; 2017; 99(1):1-5. PubMed ID: 28601885
[TBL] [Abstract][Full Text] [Related]
8. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
[TBL] [Abstract][Full Text] [Related]
9. Renal Tuberculosis Following Intravesical Bacillus Calmette-Guérin (BCG) Immunotherapy for the Treatment of Bladder Cancer.
Bajramovic S; Alic J; Skopljak E; Chikha A; Vesnic S; Smajilbegovic V; Aganovic D
Med Arch; 2020 Apr; 74(2):146-150. PubMed ID: 32577059
[TBL] [Abstract][Full Text] [Related]
10. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
[TBL] [Abstract][Full Text] [Related]
11. A magnetic chitosan hydrogel for sustained and prolonged delivery of Bacillus Calmette-Guérin in the treatment of bladder cancer.
Zhang D; Sun P; Li P; Xue A; Zhang X; Zhang H; Jin X
Biomaterials; 2013 Dec; 34(38):10258-66. PubMed ID: 24070571
[TBL] [Abstract][Full Text] [Related]
12. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
Steinbach F; Schuster F
Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
[TBL] [Abstract][Full Text] [Related]
13. Co-delivery of oxaliplatin prodrug liposomes with Bacillus Calmette-Guérin for chemo-immunotherapy of orthotopic bladder cancer.
Ma C; Zhong X; Liu R; Yang X; Xie Z; Zhang Y; Xu Y; Wang H; He C; Du G; Gong T; Sun X
J Control Release; 2024 Jan; 365():640-653. PubMed ID: 38042374
[TBL] [Abstract][Full Text] [Related]
14. Assessing the Feasibility of Replacing Standard-Dose Bacillus Calmette-Guérin Immunotherapy with Other Intravesical Instillation Therapies in Bladder Cancer Patients: A Network Meta-Analysis.
Wu C; Zhou X; Miao C; Zhang J; Tang Q; Chang X; Ni H
Cell Physiol Biochem; 2017; 41(4):1298-1312. PubMed ID: 28278504
[TBL] [Abstract][Full Text] [Related]
15. [Sepsis and multiple organ failure after BCG-instillation for bladder cancer].
Elmer A; Bermes U; Drath L; Büscher E; Viertel A
Internist (Berl); 2004 Aug; 45(8):935-9. PubMed ID: 15138643
[TBL] [Abstract][Full Text] [Related]
16. Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections.
Larsen ES; Joensen UN; Poulsen AM; Goletti D; Johansen IS
APMIS; 2020 Feb; 128(2):92-103. PubMed ID: 31755155
[TBL] [Abstract][Full Text] [Related]
17. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin.
Ratliff TL; Palmer JO; McGarr JA; Brown EJ
Cancer Res; 1987 Apr; 47(7):1762-6. PubMed ID: 3545453
[TBL] [Abstract][Full Text] [Related]
18. Reiter's syndrome postintravesical Bacillus Calmette-Guérin instillations.
Ng KL; Chua CB
Asian J Surg; 2017 Apr; 40(2):163-165. PubMed ID: 25183290
[TBL] [Abstract][Full Text] [Related]
19. Histopathology of Disseminated Mycobacterium bovis Infection Complicating Intravesical BCG Immunotherapy for Urothelial Carcinoma.
Larsen BT; Smith ML; Grys TE; Vikram HR; Colby TV
Int J Surg Pathol; 2015 May; 23(3):189-95. PubMed ID: 25614462
[TBL] [Abstract][Full Text] [Related]
20. Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette-Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway.
Mao MH; Huang HB; Zhang XL; Li K; Liu YL; Wang P
Biomed Pharmacother; 2018 Nov; 107():1093-1103. PubMed ID: 30257321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
